Market news: The full Phase III study results published in the New England Journal of Medicine showed that Eli Lilly's (LLY.N) oral obesity drug Orforglipron showed convincing efficacy and safety, consistent with injectable GLP-1 drugs.

2025-06-21 21:08:56

Lilly

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Beijing, the "capital of open source", accelerates the construction of domestic open source big models and achieves another breakthrough
                            2025-07-25

                                    PICO and Blender Foundation enter into partnership
                            2025-07-23

                                    The world's first active safety AI battery cell goes into mass production
                            2025-07-27

                                    Jida Zhengyuan was selected into Huawei Digital Government High-Quality Service Industry Alliance
                            2025-07-22

                                    JD Cloud officially open-sources JoyAgent
                            2025-07-26